title: Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats.
abstract: BACKGROUND
  Ureteral obstruction is a common pathology and caused kidney fibrosis and dysfunction at late period. In this present, we investigated the antifibrotic and antiinflammatory effects of montelukast which is cysteinyl leukotriene receptor antagonist, on kidney damage after unilateral ureteral obstruction(UUO) in rats.
  
  
  METHODS
  32 rats divided four groups. Group 1 was control, group 2 was sham, group 3 was rats with UUO and group 4 was rats with UUO which were given montelukast sodium (oral 10 mg/kg/day). After 14 days, rats were killed and their kidneys were taken and blood analysis was performed. Tubular necrosis, mononuclear cell infiltration and interstitial fibrosis scoring were determined histopathologically in a part of kidneys; nitric oxide(NO), malondialdehyde(MDA) and reduced glutathione(GSH) levels were determined in the other part of kidneys. Urea-creatinine levels were investigated at blood analysis. Statistical analyses were made by the Chi-square test and one-way analysis of variance (ANOVA).
  
  
  RESULTS
  There was no difference significantly for urea-creatinine levels between groups. Pathologically, there was serious tubular necrosis and fibrosis in group 3 and there was significantly decreasing for tubular necrosis and fibrosis in group 4(p<0.005). Also, there was significantly increasing for NO and MDA levels; decreasing for GSH levels in group 3 compared the other groups(p<0.005).
  
  
  CONCLUSIONS
  We can say that montelukast prevent kidney damage with antioxidant effect, independently of NO.
authors.affiliation: Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
authors.forename: Alper
authors.initials: A
authors.lastname: Otunctemur
authors.affiliation: Department of Urology, Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.
authors.forename: Emin
authors.initials: E
authors.lastname: Ozbek
authors.affiliation: Department of Urology, Bayburt State Hospital, Bayburt, Turkey.
authors.forename: Suleyman Sami
authors.initials: SS
authors.lastname: Cakir
authors.affiliation: Department of Urology, Bahcelievler State Hospital, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Dursun
authors.affiliation: Department of biochemistry, Kocaeli University, , Kocaeli, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Cekmen
authors.affiliation: Department of Urology, Istanbul Medipol University, Faculty of Medicine, Istanbul, Turkey.
authors.forename: Emre Can
authors.initials: EC
authors.lastname: Polat
authors.affiliation: Department of Urology, Derince Training and Research Hospital, Kocaeli, Turkey.
authors.forename: Levent
authors.initials: L
authors.lastname: Ozcan
authors.affiliation: Department Pathology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.
authors.forename: Adnan
authors.initials: A
authors.lastname: Somay
authors.affiliation: Department Pathology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.
authors.forename: Nurver
authors.initials: N
authors.lastname: Ozbay
mesh_terms: D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003404:Creatinine / Q000097:blood; D003521:Cyclopropanes; D003545:Cysteine / Q000037:antagonists & inhibitors*; D005355:Fibrosis / Q000517:prevention & control; D005978:Glutathione / Q000032:analysis; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D020024:Leukotriene Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D015289:Leukotrienes; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D009569:Nitric Oxide / Q000032:analysis; D018384:Oxidative Stress / Q000187:drug effects; D020011:Protective Agents / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D015203:Reproducibility of Results; D013440:Sulfides; D016896:Treatment Outcome; D014508:Urea / Q000097:blood; D014517:Ureteral Obstruction / Q000150:complications*
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D020011:Protective Agents; D011804:Quinolines; D013440:Sulfides; C112381:cysteinyl-leukotriene; D009569:Nitric Oxide; D008315:Malondialdehyde; D014508:Urea; D003404:Creatinine; D005978:Glutathione; D003545:Cysteine; C093875:montelukast